Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a small, nonrandomized pilot study enrolling up to 10 adults who previously had surgical resection of pancreatic ductal adenocarcinoma and are being monitored for recurrence. Investigators will use a Logiq E10 ultrasound with contrast to image the area of the original surgery to see if CEUS can identify local recurrence. The study will compare CEUS findings against standard imaging results to assess practicality and potential utility. CEUS contrast agents are expected to enhance imaging signals with favorable safety, though the most serious risk is rare anaphylactic reaction. No treatment is administered; the goal is to determine whether CEUS can help detect local disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:

  1. Be a patient that underwent surgical resection of PDAC located in the head or body of the pancreas and are being followed for recurrence with CT imaging as part of their standard of care.
  2. Be 18 years of age or older.
  3. If the subject is of child-bearing potential, must have a negative pregnancy test.
  4. Be conscious and able to comply with study procedures.
  5. Have read and signed the IRB approved consent form for participating in the study.

Exclusion Criteria:

* An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Females who are pregnant or nursing.
  2. Patients who have received an investigational drug in the 30 days before study drug administration or will receive one within 72 hours afterwards.
  3. Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:

     * Patients on life support or in a critical care unit.
     * Patients with clinically unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)
     * Patients with recent cerebral hemorrhage (within 1 month).
  4. Patients who have undergone surgery within 24 hours prior to the study ultrasound imaging examination.
  5. Patients with congenital heart defects.
  6. Patient with a known allergy to Lumason.

Where it's running

• Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Priscilla Machado, MD, FAIUM — Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
• Study coordinator: Site Public Contact
• Email: ONCTrialNow@jefferson.edu
• Phone: 215-600-9151

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas

  This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.

  Recruiting Minia University · Minya, Minya Governorate · NCT07155525

• Mesopancreas removal during Whipple surgery for pancreatic head cancer

  This will test whether adding mesopancreatic excision to the Whipple operation helps people with resectable pancreatic head cancer have fewer local recurrences and live longer.

  Recruiting Minia University · Minya, Minya Governorate · NCT07148830

• PTM-101 treatment for pancreatic cancer

  This study is testing a new treatment called PTM-101 combined with chemotherapy to see if it can help people with certain types of pancreatic cancer who haven't had treatment before.

  Recruiting at 9 sites Phase 1 PanTher Therapeutics · Newport Beach, California and 8 other locations · NCT06673017

• AI-based early detection of pancreatic cancer using routine CT scans

  This study is testing an AI system that uses regular CT scans to see if it can help find pancreatic cancer early in people who are at high risk.

  Recruiting at 3 sites Changhai Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT06638866

• Early detection of pancreatic cancer using exosome-based biomarkers

  This study is testing a new way to find pancreatic cancer early by looking at tiny particles in the blood that carry specific markers.

  Recruiting at 11 sites City of Hope Medical Center · Phoenix, Arizona and 12 other locations · NCT06388967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.